Citations

Clear

410 citation(s) found for "Shu, Yu".

Immune Checkpoint Inhibitors for Mismatch Repair–Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo Clinic
Sahwan, Oudai , Jamal, Fares , Pai, Rish K. , Eslinger, Cody , McCue, Shaylene , Borad, Mitesh J. , Zhu, Mojun , Pai, Priya K. , Xie, Hao , McWilliams, Robert R. , Wasif, Nabil , Starr, Jason S. , Yoon, Harry H. , Ahn, Daniel H. , Pai, R K , Borad, Mitesh J , Pai, Priya , McWilliams, Robert R , Tran, Nguyen , Grotz, Travis E , Ou, Fang-Shu , Wasif, Nabil , Starr, Jason S , Bekaii-Saab, Tanios S , Wu, Christina , Yoon, Harry H , Ahn, Daniel H , Sonbol, Mohamad B , Xie, Hao , Sahwan, Oudai , Jamal, Fares , Tran, Nguyen H. , Grotz, Travis E. , Ou, Fang‐Shu , Bekaii‐Saab, Tanios , Wu, Christina , Sonbol, Mohamad Bassam

Mayo Clinic

JCO Precision Oncology | November 20, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-25-00492 | PMID 41264897 Get It

PURPOSE Neoadjuvant immune checkpoint inhibitors (nICIs) have demonstrated high response rates in deficient mismatch repair/microsatellite instability–high (dMMR/MSI-H) gastroesophageal adenocarcinoma (GEA). The NEONIPIGA and INFINITY trials demonstrated high rates of pathologic complete response (pCR) in this patient population. Furthermore, the INFINITY trial explored the feasibility of managing these patients nonoperatively, demonstrating promising results. This study aimed to evaluate clinical outcomes of nICIs in resectable dMMR/MSI-H GEA, with a focus on the feasibility of nonoperative management (NOM). MATERIALS AND METHODS This retrospective cohort study included patients with resectable dMMR/MSI-H GEA and treated with nICIs ± surgery at the Mayo Clinic. Patients were identified from institutional records, and clinical data were retrospectively reviewed. Primary outcomes were clinical complete response (cCR) and pCR. Secondary outcomes included event-free survival (EFS), radiologic complete response (rCR), and immune-related adverse events (irAEs). RESULTS A total of 26 patients treated between April 1, 2017, and July 30, 2025, were identified. Nine patients (34.6%) underwent surgery, of whom six (66.7%) achieved pCR. Seventeen patients (65.4%) pursued NOM, with 10 (71.4%) of 14 evaluable patients achieving cCR and 14 (82.4%) of 17 evaluable achieving rCR. One patient who initially achieved cCR had a local recurrence on surveillance endoscopy and underwent salvage endoscopic resection. At a median follow-up of 19.3 months, 15 (88.2%) of 17 patients in the NOM cohort were alive and metastasis-free, with EFS rates of 87.3% at 12 and 24 months for all patients. irAEs occurred in nine patients (34.6%), with no grade ≥3 toxicities. CONCLUSION In this retrospective cohort study, nICIs led to high cCR and pCR rates in resectable dMMR/MSI-H GEA, supporting the use of immune checkpoint inhibitors in this setting and the feasibility of NOM in select patients.
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis
Zhang, Ting , Mohindroo, Chirayu , Wang, Xiaoyu , Dutta, Diptavo , Liu, Jia , Katta, Shilpa, Li, Shengchao A. , Wang, Jiahui , Antwi, Samuel O. , Bracci, Paige M. , Du, Mengmeng, Gallinger, Steven , Goodman, Phyllis J. , Katzke, Verena, Patel, Alpa V. , Visvanathan, Kala , Andreotti, Gabriella , Brennan, Paul , Buring, Julie E. , Chanock, Stephen J., Chen, Yu , Giovannucci, Edward L. , Haiman, Christopher A. , Hassan, Manal M. , Holly, Elizabeth A., Jones, Miranda R. , Kraft, Peter, Kurtz, Robert C. , Ng, Kimmie , Oberg, Ann L. , Peters, Ulrike , Rabe, Kari G. , Rothman, Nathaniel , Sesso, Howard D. , Yuan, Chen, Wolpin, Brian M. , Yu, Kai , Stolzenberg‐Solomon, Rachael Z. , Mohindroo, Chirayu , Wang, Xiaoyu , Dutta, Diptavo , Liu, Jia , Li, Shengchao A , Antwi, Samuel O , Arslan, Alan A , Beane Freeman, Laura E , Canzian, Federico , Du, Mengmeng , Goodman, Phyllis J , Katzke, Verena , Kooperberg, Charles , Marchand, Loïc Le , Neale, Rachel E , Perdomo, Sandra , Shu, Xiao-Ou , Visvanathan, Kala , Van Den Eeden, Stephen K , White, Emily E. , Zheng, Wei , Albanes, Demetrius , Andreotti, Gabriella , Brennan, Paul , Buring, Julie E , Chanock, Stephen Jacob , Chen, Yu , Darst, Burcu F , Ferrari, Pietro , Giovannucci, Edward L , Goggins, Michael G , Haiman, Christopher A , Hassan, Manal M , Hung, Rayjean J , Jones, Miranda R , Kraft, Peter , Malats, Nuria , Moore, Steven C , Ng, Kimmie , Oberg, Ann L , Orlow, Irene , Peters, Ulrike , Porta, Miquel , Chaffee, Kari G. , Sánchez, Maria-Jose , Sesso, Howard D , Southey, Melissa C , Um, Caroline Y , Yarmolinsky, James , Yu, Herbert , Yuan, Chen , Zhong, Jun , Wolpin, Brian M , Risch, Harvey A , Amundadottir, Laufey , Klein, Alison P , Yu, Kai , Zhang, Haoyu , Stolzenberg-Solomon, Rachael , Zhang, Ting , Hua, Xing , Arslan, Alan A. , Freeman, Laura E. Beane , Canzian, Federico , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Darst, Burcu F. , Goggins, Michael , Hung, Rayjean J. , Malats, Núria , Moore, Steven C. , Orlow, Irene , Porta, Miquel , Sánchez, María‐José , Silverman, Debra T. , Southey, Melissa C. , Um, Caroline Y. , Yu, Kai , Risch, Harvey A. , Ámundadóttir, Laufey T. , Klein, Alison P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 8, 2025 | Volume: 118 | Issue: 3 | Pages: 437-447

10.1093/jnci/djaf308 | PMID 41206949 Get It

Abstract Background The associations between different types of diabetes, characterized by distinct pathophysiology and genetic architecture, and pancreatic ductal adenocarcinoma (PDAC) risk are not understood. Methods We investigated associations of genetic susceptibility to type 2 diabetes (T2D), 8 T2D mechanistic clusters, type 1 diabetes (T1D), and maturity-onset diabetes of the young (MODY) with PDAC risk. We used genome-wide association study (GWAS) summary-level statistics for T2D (242 283 cases, 1 569 734 controls), T1D (18 942 cases, 501 638 controls), and PDAC (10 244 cases and 360 535 controls) in individuals of European ancestry. Results Two-sample Mendelian randomization (MR) using the Robust Adjusted Profile Score (MR-RAPS) method indicated that genetically predicted T2D was associated with PDAC risk (OR = 1.10; 95% CI = 1.05 to 1.15), particularly the T2D obesity (OR = 1.28; 95% CI = 1.15 to 1.42) and lipodystrophy (OR = 1.25; 95% CI = 1.03 to 1.51) clusters. No association was observed for T1D with PDAC risk (OR = 1.01; 95% CI = 0.99 to 1.02). Pathway/gene-set analysis using the summary-based Adaptive Rank Truncated Product (sARTP) method revealed a significant association between the MODY gene-sets and PDAC risk (P = 1.5 × 10−8), which remained after excluding 20 known PDAC GWAS loci (P = 7.6 × 10−4). HNF1A, FOXA3, and HNF4A were the top contributing genes after excluding the previously identified GWAS loci regions. Conclusions Our results from this genetic association study support that T2D, particularly the obesity and lipodystrophy mechanistic clusters, and MODY genomic susceptibility regions play a role in the etiology of PDAC.
Threshold-Based Overlap of Breast Cancer High-Risk Classification Using Family History, Polygenic Risk Scores, and Traditional Risk Models in 180,398 Women
Ho, Peh Joo , Loo, Christine Kim Yan , Lim, Ryan Jak Yang, Goh, Mui Heng, Abubakar, Mustapha , Ahearn, Thomas U. , Andrulis, Irene L. , Antonenkova, Natalia, Aronson, Kristan J. , Augustinsson, Annelie , Behrens, Sabine , Bodelón, Clara , Bogdanova, Natalia , Bolla, Manjeet K. , Brantley, Kristen D. , Brenner, Hermann , Byers, Helen L., Camp, Nicola J. , Cessna, Melissa H., Chang-Claude, Jenny, Choi, Ji-Yeob , Czene, Kamila , Dörk, Thilo , Eliassen, A. Heather , Engel, Christoph , Eriksson, Mikael , Evans, D. Gareth , Fritschi, Lin , Genkinger, Jeanine M. , Geurts-Giele, Willemina R.R. , Glendon, Gord, Hall, Per , Hamann, U. , Ho, Cecilia Y.S., Hooning, Maartje J. , Hoppe, Reiner , Humphreys, Keith , Ito, Hidemi , Jakubowska, Anna , Jernström, Helena , John, Esther M. , Johnson, Nichola , Kang, Daehee , Kim, Sung‐Won , Kitahara, Cari M. , Ko, Yon-Dschun, Kraft, Peter, Kwong, Ava , Lambrechts, Diether, Larsson, Susanna C. , Li, Shuai , Lindblom, Annika , Linet, Martha, Lissowska, Jolanta , Lophatananon, Artitaya , MacInnis, Robert J. , Mannermaa, Arto, Manoukian, Siranoush, Margolin, Sara, Matsuo, Keitaro , Michailidou, Kyriaki , Taib, Nur Aishah Mohd , Murphy, Rachel A. , Newman, William G. , Obi, Nadia , Olopade, Olufunmilayo I., Panayiotidis, Mihalis I. , Park, Sue K. , Park‐Simon, Tjoung‐Won , Patel, Alpa V , Peterlongo, Paolo , Plaseska‐Karanfilska, Dijana , Pylkäs, Katri , Rashid, Muhammad Usman , Rodríguez, Juan , Sandler, Dale P. , Sawyer, Elinor J. , Scott, Christopher G. , Shahi, Shamim , Shu, Xiao‐Ou , Shulman, Katerina, Simard, Jacques , Southey, Melissa C., Stone, Jennifer , Taylor, Jack A. , Teo, Soo‐Hwang , Teras, Lauren R. , Vachon, Celine M., Houdt, Maxime Van , Verhoeven, Jelle , Weinberg, Clarice R. , Wolk, Alicja , Yamaji, Taiki , Yip, Cheng Har , Zheng, Wei , Hartman, Mikael , Li, Jingmei , Investigators, on behalf of the ABCTB, Investigators, kConFab, Investigators, MyBrCa, Investigators, SGBCC, Olopade, Olufunmilayo I. , Lambrechts, Diether , Lambrechts, Diether , Hamann, Ute , Hooning, Maartje J. , Bogdanova, Natalia V , Czene, Kamila , Dörk, Thilo , Eliassen, A Heather , Engel, Christoph , Eriksson, Mikael , Evans, D Gareth , Fletcher, Olivia , Fritschi, Lin , Genkinger, Jeanine , Hall, Per N , Ho, Cecilia Y S , Humphreys, Keith , Ito, Hidemi , Jakubowska, Anna , Jernström, Helena , Johnson, Nichola , Kim, Sung-Won , Kitahara, Cari M , Kwong, Ava , Larsson, Susanna C , Li, Shuai , Lindblom, Annika , Lissowska, Jolanta , Lophatananon, Artitaya , Maclnnis, Robert , Matsuo, Keitaro , Michailidou, Kyriaki , Mohd Taib, Nur Aishah , Murphy, Rachel A , Newman, William G , Obi, Nadia , Panayiotidis, Mihalis I , Park, Sue K , Park-Simon, Tjoung-Won , Peterlongo, Paolo , Plaseska-Karanfilska, Dijana , Pylkäs, Katri , Rashid, Muhammad U , Rennert, Gad , Rodriguez, Juan , Sandler, Dale P , Sawyer, Elinor J , Scott, Christopher , Shu, Xiao-Ou , Simard, Jacques , Stone, Jennifer , Taylor, Jack A , Teo, Soo H , Teras, Lauren R , Houdt, Maxime Van , Verhoeven, Jelle , Weinberg, Clarice R , Wolk, Alicja , Zheng, Wei , Hartman, Mikael , Li, Jingmei , Lambrechts, Diether , Behrens, Sabine , John, Esther M , Olopade, Olufunmilayo I , Lambrechts, Diether , Augustinsson, Annelie , Brenner, Hermann , Camp, Nicola J , Brantley, Kristen D , Lim, Ryan Jak Yang, Byers, Helen, Castelao, Jose E. , Chang‐Claude, Jenny , Chanock, Stephen Jacob , Chenevix‐Trench, Georgia , Colonna, Sarah V. , Daly, Mary Beryl , Derouane, Françoise , Fletcher, Olivia , Gago-Domínguez, Manuela , Ho, Weang-Kee , Howell, Anthony , Iwasaki, Motoki , Ko, Yon‐Dschun, Mannermaa, Arto , Manoukian, Siranoush , Margolin, Sara , Milne, Roger L. , Muir, Kenneth , O’Brien, Katie M. , Rennert, Gad , Saloustros, Emmanouil , Southey, Melissa C. , Terry, Mary Beth , Torres, Diana , Investigators, on behalf of the ABCTB, Investigators, kConFab, Investigators, MyBrCa, Investigators, SGBCC

Mayo Clinic

Cancers | November 3, 2025 | Volume: 17 | Issue: 21 | Pages: 3561

10.3390/cancers17213561 | PMID 41228354 Get It

Background: Breast cancer polygenic risk scores (PRS) and traditional risk models (e.g., the Gail model [Gail]) are known to contribute largely independent information, but it is unclear how the overlap varies by ancestry, age, disease type (invasive breast cancer, DCIS), and risk threshold. Methods: In a retrospective case–control study, we evaluated risk prediction performance in 180,398 women (161,849 of European ancestry; 18,549 of Asian ancestry). Odds ratios (ORs) from logistic regression models and the area under the receiver operating characteristic curve (AUC) were estimated. Results: PRS for invasive disease showed a stronger association in younger (<50 years) women (OR = 2.51, AUC = 0.622) than in women ≥ 50 years (OR = 2.06, AUC = 0.653) of European ancestry. PRS performance in Asians was lower (OR range = 1.62–1.64, AUC = 0.551–0.600). Gail performance was modest across groups and poor in younger Asian women (OR = 0.94–0.99, AUC = 0.523–0.533). Age interactions were observed for both PRS (p < 0.001) and Gail (p < 0.001) in Europeans, whereas in Asians, age interaction was observed only for Gail (invasive: p < 0.001; DCIS: p = 0.002). PRS identified more high-risk individuals than Gail in Asian populations, especially ≥50 years, while Gail identified more in Europeans. Overlap between PRS, Gail, and family history was limited at higher thresholds. Calibration analysis, comparing empirical and model-based ROC curves, showed divergence for both PRS and Gail (p < 0.001), which indicates miscalibration. In Europeans, family history and prior biopsies drove Gail discrimination. In younger Asians, age at first live birth was influential. Conclusions: PRS adds value to risk stratification beyond traditional tools, especially in younger women and Asian ancestry populations.
Impaired Perfusion and Early Ischemic Stroke Recurrence in Symptomatic Intracranial Atherosclerosis: BIORISK ICAS Study
Yaghi, Shadi , Khan, Farhan , Lewis, Skylar, Stipanovich, Ava, Choi, Richard , Baker, Richard, Kasab, Sami Al , Qdais, Ahmad Abu, Yaddanapudi, Sridhara , Sultana, Sabiha , Khan, Muhib , Malik, Maarij , Klaas, James P. , Bakradze, Ekaterina , Ressler, Hadley W. , McCullough‐Hicks, Margy , Cooper, Dawson C , Pillai, Abhiram Parameswaran, Hariharan, Praveen , Alam, Shaista , Mayer, Morgan, Kugler, Irina, Almiri, William , Secchi, Thaís , Mantovani, Gabriel Paulo , Rothstein, Aaron , Krishnaiah, Balaji , Alfred, Linda Sherine , Vishnu, Venugopalan Y. , Chandu, Meena, Agarwal, Ayush , Marrone, Nicola , Vozzi, Stefano, Ghannam, Malik , Elshikh, Mohamed , Hou, Yan , Peshwe, Krithika Umesh, Tunguturi, Ajay, Frontera, Jennifer , Zaidat, Osama O. , Barakat, Benan , Khan, Niha, Sen, Shayak, Coelho, Mariana Lima , Sousa, João André , Sousa, Diana Aguiar de , Soares, Mafalda , Rodrigues, Amanda Cyntia Lima Fonseca , Jhaveri, Aditya , Bhati, S., Vassilopoulou, Sofia , Tountopoulou, Argyro , Muddasani, Varsha , Henninger, Nils , Tran, Hieu , Helenius, Johanna, Khasawneh, Mohammad W , Vellimana, Ananth K. , Apfel, Ryan , Molaie, Amir , Mannino, Marina , Terruso, Valeria, Halabi, Tarek El , Reda, Mahasen , Tamer, Christel, Shu, Liqi , Khatri, Pooja , Furie, Karen L. , Liebeskind, David S. , Al Kasab, Sami , Klaas, James P , Aemaz Ur Rehman, Muhammad , Leon Guerrero, Christopher R , Ressler, Hadley Walsh , Saleh Velez, Faddi , Owens, Cameron , McCullough-Hicks, Margy , Cooper, Dawson , Parameswaran Pillai, Abhiram , Hariharan, Praveen , Heldner, Mirjam R , Antonenko, Kateryna , Almiri, William , Martins, Sheila , Mantovani, Gabriel , Rothstein, Aaron , Sloane, Kelly L , Krishnaiah, Balaji , Elangovan, Cheran , Vishnu, Venugopalan Y , Chandu, Meena , Agarwal, Ayush , Romoli, Michele , Ghannam, Malik , Elshikh, Mohamed , Dibas, Mahmoud , Hou, Yan , Tunguturi, Ajay , Marto, João Pedro , Duarte Armindo, Rui , Frontera, Jennifer , Kuohn, Lindsey , Almajali, Mohammad , Zaidat, Osama O , Barakat, Benan , Simpkins, Alexis N , Coelho, Mariana , Sargento-Freitas, Joao , Sousa, Joao Andre , Aguiar de Sousa, Diana , Soares, Mafalda , Cyntia Lima Fonseca Rodrigues, Amanda , Jhaveri, Aditya , Morsi, Rami Z , Siegler, James E , Aziz, Yasmin , Harker, Pablo , Vassilopoulou, Sofia , Tountopoulou, Argyro , de Havenon, Adam H , Henninger, Nils , Tran, Hieu , Khasawneh, Mohammad , Vellimana, Ananth , Apfel, Ryan , Molaie, Amir , Mannino, Marina , Terruso, Valeria , Klein, Piers , Shu, Liqi , Khatri, Pooja , Furie, Karen L , Nguyen, Thanh N , Liebeskind, David S. , Prabhakaran, Shyam , Yaghi, Shadi , Choi, Richard , Khan, Farhan , Sultana, Sabiha, Rehman, Muhammad Aemaz Ur , Velez, Faddi G. Saleh , Pinto, Camila Bonin , Alam, Shaista, Mayer, Morgan, Heldner, Mirjam R. , Kugler, Irina, Elangovan, Cheran , Dibas, Mahmoud , Marto, João Pedro , Kuohn, Lindsey , Almajali, Mohammad , Khan, Niha, Simpkins, Alexis N. , Sen, Shayak, Morsi, Rami Z. , Siegler, James E. , Aziz, Yasmin , Harker, Pablo , Bhati, Sonia, Havenon, Adam de , Tamer, Christel, Klein, Piers , Nguyen, Thanh N. , Prabhakaran, Shyam

Mayo Clinic

Stroke | October 23, 2025 | Volume: 57 | Issue: 1 | Pages: 96-106

10.1161/strokeaha.125.053160 | PMID 41128719 Get It

BACKGROUND: Intracranial atherosclerosis (ICAS) is associated with an increased risk of early recurrent ischemic stroke. We evaluated whether biomarkers of impaired distal perfusion—specifically, anterior circulation borderzone infarct, and hypoperfusion mismatch volume—were associated with recurrent ischemic stroke within 90 days. METHODS: The BIORISK ICAS (Biomarkers and Recurrence Risk in Symptomatic Intracranial Atherosclerosis) is a multicenter retrospective international study (35 sites) that included hospitalized patients with symptomatic ICAS (50%–99% luminal stenosis of the intracranial vertebral, basilar, distal internal carotid, or proximal middle cerebral artery) from January 2019 to June 2024. The primary outcome was recurrent ischemic stroke in the territory of the symptomatic artery within 90 days. In the primary analysis, the exposure was an acute anterior circulation borderzone infarct. In secondary analysis of the subset with presentation within 72 hours of last known normal and perfusion imaging completed, the exposure of interest was prespecified as hypoperfusion mismatch volume at T max (time to maximum) threshold of 6 seconds, dichotomized at the Youden index. We performed multivariable Cox regression to test associations between exposure variables and the outcome, adjusting for clinically relevant variables and those associated with the outcome ( P <0.1). RESULTS: Of 2050 patients with symptomatic ICAS, 1737 (84.7%) presented within 72 hours of symptom onset, among whom 509 (29.3%) underwent perfusion imaging. The primary analysis included 1891 patients; 174 (9.2%) patients had recurrent ischemic stroke in the symptomatic arterial territory. In adjusted Cox regression models, there was an association between anterior circulation borderzone infarct and recurrent ischemic stroke at 90 days (adjusted hazard ratio, 1.40 [95% CI, 1.02–1.93]). In the perfusion imaging analysis, hypoperfusion mismatch of ≥10 mL was associated with recurrent ischemic stroke (adjusted hazard ratio, 1.83 [95% CI, 1.03–3.28]). CONCLUSIONS: Biomarkers of impaired distal perfusion, anterior circulation borderzone infarct, and hypoperfusion mismatch were associated with increased risk of recurrent ischemic stroke. These findings support the use of perfusion imaging in ICAS as well as future trials investigating early reperfusion in high-risk patients with ICAS.
Sustained Improvement in Kidney Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: Three-Year Results from the PaTH Forward and PaTHway Trials
Gosmanova, Elvira O. , Khan, Aliya , Shoback, Dolores , Kohlmeier, Lynn, Rubin, Mishaela R. , Zhao, Carol, Makara, Michael, Lai, Bryant, Ukena, Jenny, Schwarz, Peter , Rejnmark, Lars , Clarke, B.L. , Cetani, Filomena , Sprague, Stuart Michael , Palermo, Andrea, Gagnon, Claudia , Tsourdi, Elena , Zhao, Carol, Sibley, Christopher T. , Shu, Aimee D

Mayo Clinic

Journal of the American Society of Nephrology | October 23, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.20253yamgex4 Get It

OR10-05 Efficacy and Safety of Palopegteriparatide Treatment in Adults With Hypoparathyroidism: 3-Year Results From The Phase 3 PaTHway Trial
Khan, Aliya , Rubin, Mishaela R. , Shoback, Dolores , Palermo, Andrea, Abbott, Lisa G, Kohlmeier, Lynn, Jain, Rajesh Kumar , Zhao, Carol, Lai, Bryant, Makara, Michael, Ukena, Jenny, Clarke, B.L. , Schwarz, Peter , Gagnon, Claudia , Tsourdi, Elena , Cetani, Filomena , Zhao, Carol, Sibley, Christopher T. , Shu, Aimee D , Rejnmark, Lars

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.560 Get It

Abstract Disclosure: A.A. Khan: Alexion Pharmaceuticals, Inc., Amgen Inc, Amolyt Pharma, Ascendis Pharma. B.L. Clarke: Amolyt Pharma, Ascendis Pharma, EnteraBio, Extend Bio, Takeda. M.R. Rubin: Ascendis Pharma, MBX Biosciences. P.E. Schwarz: Aventis Pharmaceuticals, Genmab, Novo Nordisk. D.M. Shoback: Ascendis Pharma. C. Gagnon: Amgen Inc, Ascendis Pharma, Novo Nordisk, Shire, Takeda. A. Palermo: None. L.G. Abbott: Abbott Laboratories, Ascendis Pharma, Clarus, Shire, Takeda. L. Kohlmeier: Amgen Inc, Ascendis Pharma, Radius Health, Inc. E. Tsourdi: Alexion Pharmaceuticals, Inc., Ascendis Pharma, Kyowa Kirin, Takeda, UCB. F. Cetani: None. R. Jain: Amgen Inc, Ascendis Pharma. C. Zhao: Ascendis Pharma. B. Lai: Ascendis Pharma. M.A. Makara: Ascendis Pharma. J. Ukena: Ascendis Pharma. C.T. Sibley: Ascendis Pharma. A.D. Shu: Ascendis Pharma. L. Rejnmark: Amolyt Pharma, Ascendis Pharma, BridgeBio, Kyowa Kirin, Takeda. Background: Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH) and is associated with reduced quality of life and a high comorbidity burden. Conventional therapy for hypoparathyroidism (active vitamin D and elemental calcium) aims to alleviate hypocalcemia but does not address insufficient PTH and may increase the risk of renal complications. Palopegteriparatide is a prodrug of PTH(1-34), administered subcutaneously once daily, designed to provide active PTH within the physiological range for 24 hours/day. It is approved by the Food and Drug Administration, European Commission, and Medicines and Healthcare products Regulatory Agency. This analysis evaluated the long-term efficacy and safety of palopegteriparatide in adults with chronic hypoparathyroidism through week 156 of the PaTHway trial. Methods: PaTHway is a phase 3 trial with a 26-week randomized, double-blind, placebo-controlled period followed by an ongoing open-label extension period. Serum biochemistries were assessed at baseline and regular intervals. Renal function was assessed by estimated glomerular filtration rate (eGFR). Safety assessments included 24-hour urine calcium and treatment-emergent adverse events (TEAEs). Results: At week 156, 89% (73/82) of participants remained in the trial; of those, 96% were independent from conventional therapy (no active vitamin D and ≤600 mg/day elemental calcium) and 88% had normal albumin-adjusted serum calcium levels (8.3-10.6 mg/dL) with a mean (SD) of 8.9 (0.6) mg/dL. Mean (SD) serum phosphate (3.4 [0.6] mg/dL) and calcium x phosphate product (30.6 [5.4] mg2/dL2) levels remained within normal ranges through week 156. Mean (SD) eGFR at week 156 was 78.0 (14.5) mL/min/1.73 m2, reflecting a mean (SD) increase of 8.8 (11.9) mL/min/1.73 m2 from baseline (P&lt;0.0001); 59% and 43% of participants had an increase in eGFR of ≥5 mL/min/1.73 m2 and ≥10 mL/min/1.73 m2, respectively. Among participants with baseline eGFR &lt;60 mL/min/1.73 m2 (n=23), the mean (SD) increase in eGFR was 14.0 (8.9) mL/min/1.73 m2 from baseline to week 156. Mean (SD) 24-hour urine calcium levels normalized with palopegteriparatide treatment, remaining below the upper limit of normal (≤250 mg/day) through week 156 (162.1 [117.8] mg/day). TEAEs were mostly grade 1 or 2, with no new safety signals identified. Conclusion: Through year 3 of the PaTHway trial, retention rate was high and palopegteriparatide demonstrated consistent longer-term safety and efficacy, which included the maintenance of serum and urine biochemistries within normal levels and sustained improvement in renal function. Presentation: Saturday, July 12, 2025
B-036 Paving the path for autonomous mobile robots (AMRs) in the clinical laboratory: A pilot study of Collaborative Robotics (Cobot) Proxie robot for cart movement at Mayo Clinic Laboratories
Lewis, Dakota, Pearce, Kathryn E., Riley, Amanda K. , Stellmaker, Jessica A. , Andrijasevic, Dario, Reese-Davis, Angela, Mudler, Leah, Freyholtz, Carl, Rosier, Ashley S. , Fischer, Stephen , Thiessen, Tanner, Jiang, Shu , Lomi, John, Syznal, Jaemie, Koch, Justin, Devine, Daniel , Baumann, N, Riley, Amanda, Andrijasevic, Dario, Freyholtz, Carl D., Koch, Justin, Devine, Daniel

Mayo Clinic

Clinical Chemistry | October 2, 2025 | Volume: 71 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvaf086.434 Get It

Abstract Background The use of autonomous mobile robots (AMRs) to move materials/supplies is long-standing in manufacturing/warehouse settings and is expanding into hospitals and clinical laboratories. The recently launched Proxie robot (Collaborative Robotics i.e. Cobot) is an AMR that can autonomously move existing carts between defined locations. However, AMRs pose new challenges compared to traditional lab automation. The aims of this study were to: i) perform functional validation to verify Proxie*s manufacturer performance specifications within the laboratory, ii) assess the risk of using Proxie to deliver laboratory specimens, and iii) pilot the use of the Proxie robot to autonomously deliver loaded carts from the Pathology case intake area to the sorting station at Mayo Clinic Laboratories. Methods Functional validation of Proxie consisted of verifying manufacturer’s performance specifications for the following robot parameters (5 test runs): maximum speed, emergency-stop, and ability to maintain localization, travel autonomously, stop and/or avoid moving/fixed objects, and park/unpark. Risk assessment for the robotic use case was performed by a multi-disciplinary team utilizing an AMR risk assessment tool developed by the institutional robotics group. Hazards were categorized as mechanical, electrical, noise, ergonomic, environmental, material/substance or combination risks. Injury severity, exposure(frequency), and avoidance scores were assigned to each hazard to determine negligible-, low-, medium-, high- or very high-risk levels. Proxie’s workstream was evaluated weekly over four weeks by measuring number of cart deliveries, total time/miles traveled, % autonomous deliveries(goal &gt;80%), % on-time deliveries, average±standard deviation(SD) time (min:sec±min:sec) for delivery/return trips, and dwell times at intake/sorting stations. Results Manufacturer’s performance specifications were verified in 100% of test runs. Proxie traveled at human walking speed, stopped within 1 second of emergency stop being enabled, maintained localization, and traveled autonomously for =5 consecutive workflow cycles. Proxie navigated through spaces =4’ wide along fixed pathways and stopped safely when encountering obstacles. Proxie navigated around people and carts in the main 6’ hallway if they were blocking &lt;2’ hallway width. For objects blocking &gt;2’, Proxie stopped and resumed motion after the object moved. After task completion, Proxie side-shifted into the AMR parking space stopping no closer than 7.8” from any object. Twenty-four potential hazards were identified through the risk assessment tool with all risk levels scored as negligible or low. Proxie completed 304 cart deliveries/returns operating 17:35 hours and traveling 11.5 miles during the pilot. The % autonomous deliveries for week 1-4 was 82%,88%,91% and 88%, respectively with =99% on-time deliveries. Delivery from pathology case intake to sorting station averaged 5:43±0:25 min and return trips averaged 3:32±0:34. Proxie dwell times were 13:10±0:33 and 37:34±0:23 min at the pathology intake and sorting stations, respectively. Conclusions The Proxie AMR was capable of successfully and autonomously moving carts with laboratory specimens between the pathology intake and sorting stations of the laboratory during the pilot study. Adding Proxie to this workstream translated to eliminating 5,800 steps and 4 hours 24 min of human cart-pushing per week. Incorporating Proxie into laboratory operations as a cart-moving AMR would increase efficiency and allow laboratory staff to focus on technical, non-repetitive work.
Large language models for bioinformatics
Ruan, Wei, Lyu, Yanjun , Zhang, Jing , Cai, Jiazhang , Lu, Yao , Wang, Tao , Liu, Yufang , Fang, Luyang , Liu, Ziyu , Liu, Zhengliang , Li, Yiwei , Wu, Zihao , Chen, Junhao , Jiang, Hanqi, Yang, Zhenyuan, Liang, Shizhe, Zhang, Wei , Ma, Terry, Dou, Yuan , Zhang, Jianli , Gong, Xinyu , Gan, Qi , Zou, Yusong , Chen, Z. J. , Qian, Yuanxin, Yu, Shuo , Song, Kenan, Sikora, Andrea, Li, Xiang , Wang, Yingfeng , Zhong, Wenxuan, Liu, Rongjie , Huang, Chao , Shen, Ye , Yan, Yajun , Liu, Tianming, Huang, Chao , Song, Kenan , Wang, Peilong, Chen, Jingyuan, Song, Kenan , Ruan, Wei, Shu, Peng , Yang, Ge , Gao, Shang , Wang, Yue , Wang, Peilong , Zhao, Lin , Jiang, Hanqi , Pan, Yi Feng , Chen, Jingyuan , Dou, Yuan, Chen, Z. J. , Qian, Yuanxin, Jin, Lu , Wang, Xianqiao , Sikora, Andrea , Li, Gang , Li, Quanzheng , Zhang, Lu, Abate, Yohannes , He, Lifang , Zhong, Wenxuan, Liu, Wei , Ma, Ping , Zhu, Hongtu , Zhu, Dajiang

Mayo Clinic

Quantitative Biology | September 29, 2025 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/qub2.70014 | PMID 41676319 Get It

Abstract With the rapid advancements in large language model technology and the emergence of bioinformatics‐specific language models (BioLMs), there is a growing need for a comprehensive analysis of the current landscape, computational characteristics, and diverse applications. This survey aims to address this need by providing a thorough review of BioLMs, focusing on their evolution, classification, and distinguishing features, alongside a detailed examination of training methodologies, datasets, and evaluation frameworks. We explore the wide‐ranging applications of BioLMs in critical areas such as disease diagnosis, drug discovery, and vaccine development, highlighting their impact and transformative potential in bioinformatics. We identify key challenges and limitations inherent in BioLMs, including data privacy and security concerns, interpretability issues, biases in training data and model outputs, and domain adaptation complexities. Finally, we highlight emerging trends and future directions, offering valuable insights to guide researchers and clinicians toward advancing BioLMs for increasingly sophisticated biological and clinical applications.
Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study
Hussain, Yessar, Malhotra, Saurabh , Sperry, Brett W. , Shu, Francy , Ananthasubramaniam, Karthikeyan , Desai, Urvi , Egolum, Ugochukwu , Fernandez, Joel , Freimer, Miriam , Mauricio, Elizabeth A. , Quan, Dianna , Small, Roy S., Capocelli, Kelley E. , Roblin, Steven, Bender, Shaun , Jay, Patrick Y. , Yureneva, Elena, Zolty, Ronald , Mauricio, Elizabeth A. , Capocelli, Kelley , Sperry, Brett W

Mayo Clinic

Annals of Medicine | September 20, 2025 | Volume: 57 | Issue: 1 | Pages: No page available

10.1080/07853890.2025.2537347 | PMID 40974604 Get It

First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study
Kournoutas, Ioannis , Marell, Paulina S. , Peersen, Anina, Shah, Priyanshi , VanDommelen, Kyle, Gupta, Garima , Akce, Mehmet , Yang, Ju Dong , Chen, Pin‐Jung , Naleid, Nikolas , Peterson, Nicole , Sahai, Vaibhav , Halfdanarson, Thorvardur, Kankeu, Lionel Fonkoua, Washburn, Leslie, Conboy, Caitlin B. , Goenka, Ajit H. , Thompson, Scott A. , Ahn, Daniel H. , Jatoi, Aminah , Marell, Paulina, Gile, Jennifer , Yang, Ju Dong , Sahai, Vaibhav , Jin, Zhaohui , Fonkoua, Lionel Aurelien A Kankeu , Washburn, Leslie A, Goenka, Ajit, Starlinger, Patrick , Roberts, Lewis, Jatoi, Aminah , Ou, Fang-Shu , Tran, Nguyen , Conboy, Caitlin B , Kamath, Suneel Deepak , Mahipal, Amit , Wee, Wen , Jin, Zhaohui , Fonkoua, Lionel Aurelien Kankeu , Torbenson, Michael , Thompson, Scott, Venkatesh, Sudhakar K. , Starlinger, Patrick , Roberts, Lewis R. , Gores, Gregory J. , Babiker, Hani M. , Borad, Mitesh J. , Bekaii‐Saab, Tanios , McWilliams, Robert R. , Ou, Fang‐Shu

Mayo Clinic

The Oncologist | September 20, 2025 | Volume: 30 | Issue: 11 | Pages: No page available

10.1093/oncolo/oyaf286 | PMID 40973475 Get It

Abstract Background Unresectable hepatocellular carcinoma (uHCC) is a leading cause of cancer death. FDA-approved first-line systemic therapies include atezolizumab/bevacizumab (atezo/bev) and durvalumab/tremelimumab (durva/treme); however, there is a lack of comparative data. Methods We reviewed outcomes of patients with uHCC who initiated atezo/bev or durva/treme between 2017 and 2024, across six institutions. Overall survival (OS) and time to treatment discontinuation (TTD) were analyzed using the Kaplan–Meier and Cox models, adjusting for baseline characteristics. Results Four hundred fifty-two uHCC pts were included. Median age: 68 years; 77% male; 81% white. Most common etiologies were viral hepatitis (38.9%) and metabolic dysfunction-associated steatohepatitis (19.5%). Disease progression was the primary reason for treatment discontinuation, atezo/bev (56%) and durva/treme (42%). Outcomes were not statistically significant (median OS [month, m]: 14.0 vs 14.6 [P = .66]; median TTD [m]: 4.9 vs 3.9 [P = .42] for atezo/bev vs durva/treme). Outcomes were significantly different between Child-Pugh classes (CP: A, B7, B8/9, C) respectively, median OS(m): 19.0, 6.1, 5.1, 2.0 (P &lt; .001); median TTD(m): 6.1, 2.3, 3.0, 1.3 (P &lt; .001). Conclusions In this real-world study of uHCC, no significant difference in clinical outcomes was observed between atezo/bev and durva/treme in the first-line setting. CP scores were a key prognostic variable with both regimens.